NCT03128164已完成1 期
A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or No Standard of Care Existed
Hutchison Medipharma Limited3 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2017年8月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 3
- 主要终点
- Dose limited toxicities evaluated with NCI CTCAE v4.03
研究概览
简要总结
This is a Phase 1, open-label study of HMPL-689 administered orally to patients with lymphoma for whom failed of standard care or have no standard of care.This study consists of a dose escalation stage (Stage I) and a dose expansion stage (Stage II).
详细描述
Both Stage I and Stage II include the following periods: screening period, treatment period, safety follow-up period, and extended progression free survival (PFS) follow-up period, as defined in Dose Escalation Stage (Stage I).
Dose escalation will be performed according to a modified toxicity probability interval scheme-2 (mTPI-2).To further characterize safety and efficacy of HMPL-689 at RP2D, expansion stage of the study enrolled 144 patients with B cell lymphoma, including CLL/ SLL, FL, MZL, DLBCL, MCL and PTCL. Patients were treated with RP2D as starting dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form (ICF)
- •Ability to comply with the protocol
- •Age ≥ 18 years old
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Histologically confirmed lymphoma
- •Relapsed or refractory disease after failed of standard of care or no standard of care existed according to local guideline, and need further systematic treatment in the opinion of the investigator
- •At least 1 bi-dimensionally measurable nodal disease, defined as >1.5 cm (extra-nodal lesion>1.0 cm ) in its largest dimension by computerized tomography (CT) scan is required for patients with lymphoma other than CLL; lesions in anatomical locations (such as extremities or soft tissue lesions) that are not well visualized by CT may be measured by magnetic resonance image (MRI) instead
- •Expected survival of more than 24 weeks
- •Female patients of child-bearing potential and male patients with partners of child-bearing potential must agree to use double barrier contraception, condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), contraceptives (oral or parenteral), Implanon®, injectable or other avoidance of pregnancy measures during the study and for 30 days after the last day of treatment. Post-menopausal females (>45 years old and without menses for >1 year) and surgically sterilized females are exempt from this criterion
排除标准
- •Patients with CNS(Central nervous system) involvement
- •Any of the following laboratory abnormalities:
- •Absolute neutrophil count < 1.5×109/L Hemoglobin <90 g/L Platelets< 100 ×109/L
- •Inadequate organ function, defined by the following:
- •Total bilirubin >1.5 x the upper limit of normal (ULN) with the following exception:
- •Patients with known Gilbert's disease who have serum total and direct bilirubin level ≤ 2.5 x the ULN and normal aspartate transaminase (AST) and alanine transaminase (ALT) may be enrolled
- •AST or ALT >2.5 x the ULN with the following exception:
- •In the dose expansion stage:Patients with documented disease infiltration of the liver may have AST and ALT levels ≤ 5 x the ULN
- •Serum creatinine >1.5 x the ULN or estimated creatinine clearance (Ccr) (i.e., estimated Glomerular Filtration Rate, [eGFR[ according to the method of Cockcroft-Gault )< 60 mL/min
- •International normalized ratio (INR) >1.5 x the ULN or activated partial thromboplastin time (aPTT) >1.5 x the ULN or Prothrombin Time (PT) >1.5 x the ULN
- •Serum amylase or lipase >ULN at screening
- •Patients with presence of second primary malignant tumors within the last 5 years, with the exception of the following non-invasive malignancies after curative treatment:
- •Basal cell carcinoma of the skin Squamous cell carcinoma of the skin Carcinoma in situ of the cervix Carcinoma in situ of the breast Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for≥ 1 year prior to randomization
- •Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
- •Prior treatment with any PI3K inhibitors and discontinued due to disease progression
- •Any anti-cancer therapy, including chemotherapy, radiotherapy within 3 weeks prior to initiation of study treatment
- •G-CSF/blood transfusion is prohibited 7 days before the screening hematology test
- •Any steroid therapy or approved targeted small molecule agents for anti-neoplastic intent within 7 days or approximately 5 half-lives, whichever is the longer, prior to initiation of study treatment
- •Any monoclonal antibody for anti-neoplastic intent within 6 weeks or 2 half-lives, whichever is the longer, prior to initiation of study treatment
- •Prior use of any anti-cancer vaccine
- •Prior administration of radioimmunotherapy within 3 months prior to initiation of study treatment
- •Prior use of any drug that is a strong inducer of CYP3A4, strong inhibitor of CYP3A4 within 2 weeks prior to initiation of study treatment (refer to Appendix 13)
- •Prior autologous transplant within 6 months prior to initiation of study treatment
- •Prior allogeneic stem cell transplant within 6 months prior to initiation of study treatment or with any evidence of active graft versus host disease or requirement for immunosuppressants within 21 days prior to initiation of study treatment
- •Clinically significant active infection (e.g., pneumonia)
- •Major surgical procedure within 4 weeks prior to initiation of study treatment
- •Treatment within a clinical study of an investigational agent or using an investigational device within 30 days prior to initiation of study treatment
- •Adverse events from prior anti-cancer therapy that have not resolved to Grade 1, except for alopecia
- •Pregnant (positive pregnancy test) or lactating women
- •New York Heart Association (NYHA) Class II or greater congestive heart failure
- •Congenital long QT syndrome or QTc > 450 msec
- •Currently use medication known to cause QT prolongation or torsades de pointes
- •History of myocardial infarction or unstable angina within 6 months prior to initiation of study treatment
- •History of stroke or transient ischemic attack within 6 months prior to initiation of study treatment
- •Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease
- •History of inflammatory bowel disease (e.g., Crohn disease or ulcerative colitis)
- •History of drug-induced pneumonitis
- •Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications
研究组 & 干预措施
Six arm including in dose expansion stage by following:
Experimental
- Arm A: patients with MZL (subtype including nodal, extra-nodal and splenic) who received ≥ 1 previous line of systematic treatment and at least one line included CD20-directed regimen
- Arm B: patients with CLL/SLL who received ≥ 1 previous line of systematic treatment and at least one of which included purine-based regimen or CD20-directed regimen
- Arm C: patients with FL (grade 1, 2, and 3a) who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen
- Arm D: patients with MCL who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen
- Arm E: patients with DLBCL (including GCB and non-GCB, Richter' transformation) who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen
- Arm F: patients with PTCL who received ≥ 2 previous line of systematic treatment
干预措施: HMPL-689 (Drug)
结局指标
主要结局
Dose limited toxicities evaluated with NCI CTCAE v4.03
时间窗: within 28 days after the first dose
Incidence of dose limited toxicities and associated dose of HMPL-689
Objective response rate (ORR)
时间窗: Through study completion, 1 year after the last patient has enrolled in the study or all patients have discontinued the study, whichever comes sooner
Overall response rate (ORR) is defined as the proportion of patients who have a CR or PR
次要结局
- Maximum plasma concentration calculated with Blood samples(within 29 days after the first dose)
- Time to reach maximum concentration calculated with Blood samples(within 29 days after the first dose)
研究者
研究点 (3)
Loading locations...
相似试验
终止
1 期
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaNCT03779113Hutchmed69
终止
1 期
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersLymphoma, T-Cell, CutaneousHodgkin DiseaseLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinNCT06120504Seagen, a wholly owned subsidiary of Pfizer22
撤回
1 期
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)Blood Platelet DisorderHematologic DiseasesPurpura, ThrombocytopenicPurpuraBlood Coagulation DisorderThrombotic MicroangiopathiesHemorrhagic DisordersAutoimmune DiseasesImmune System DiseasesHemorrhagePathologic ProcessesSkin ManifestationsPurpura, Thrombocytopenic, IdiopathicPrimary Immune ThrombocytopeniaITP - Immune ThrombocytopeniaThrombocytopeniaImmune ThrombocytopeniaNCT06291415Hutchmed48
终止
1 期
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDHIsocitrate Dehydrogenase Gene MutationNCT04764474Hutchmed46
已完成
1 期
MEDI5752 in Japanese Patients With Advanced Solid Tumors.Advanced Solid TumorsNCT05685472AstraZeneca6